Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):884-885; doi:10.1093/jnci/djh162
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stearns, V.
Right arrow Articles by Flockhart, D. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stearns, V.
Right arrow Articles by Flockhart, D. A.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Vered Stearns, Michael D. Johnson, James M. Rae, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes, Zeruesenay Desta, David A. Flockhart

Affiliations of authors: Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN (DAF, ZD); Breast Cancer Program, University of Michigan, Ann Arbor (JMR, DFH); and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (VS); Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC (MDJ, AN, PB)

Correspondence to: David A. Flockhart, MD, PhD, Division of Clinical Pharmacology, Indiana University School of Medicine, 1001 W. 10th St., Rm. OPD 320, Indianapolis, IN 46203 ( e-mail: dflockha@iupui.edu)

The first 10% of the full text of this article appears below.

We thank all three correspondents for their useful insights into our work. The data we presented demonstrate that the tamoxifen metabolite 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) is equipotent to 4-hydroxy-tamoxifen in inhibiting estradiol-stimulated growth of MCF-7 cells (1) and that endoxifen concentrations were reduced in women who carried a genetic variant of CYP2D6 or in women with a wild-type CYP2D6 after coprescription with the CYP2D6 inhibitor paroxetine. The role of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Brooke Ratliff, Eric C. Dietze, Gregory R. Bean, Cassandra Moore, Sam Wanko, and Victoria L. Seewaldt
J Natl Cancer Inst 2004 96: 883. [Extract] [Full Text] [PDF]

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Riccardo Ponzone, Nicoletta Biglia, and Piero Sismondi
J Natl Cancer Inst 2004 96: 883-884. [Extract] [Full Text] [PDF]

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Ernst A. Lien, Per M. Ueland, and Per E. Lønning
J Natl Cancer Inst 2004 96: 884. [Extract] [Full Text] [PDF]